Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SNP-630 in Healthy Subjects
NCT04808154Phase 1Completed
- Sponsor
- Sinew Pharma
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNP-630 in Nonalcoholic steatohepatitis (NASH), sponsored by Sinew Pharma. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 6 days. Started Jul 2021; status: completed.
02
Drugs
SNP-630
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04808154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808154.